Parkinson's Disease
Gordon Research Conference

June 25-30, 2017
Grand Summit Hotel
Newry, ME, USA

20 years of alpha-synuclein in
Parkinson's Disease
September 7-10 2017

Hotel Mare Nostrum
Athens, Greece

NEWS & PRESS

 

Origenis Announces Patent Grants for Lead Small Molecule LRRK2 Inhibitors for Treatment of Neurodegenerative and Inflammatory Diseases

23. May 2017

Origenis Announces Patent Grants for Lead Small Molecule LRRK2 Inhibitors for Treatment of Neurodegenerative and Inflammatory Diseases

Martinsried, Germany, May 23, 2017 - Origenis GmbH, a privately held biopharmaceutical company developing novel therapeutics to fight neurodegenerative and neuroinflammatory diseases, today announced that the US Patent Office has granted the company two important patents, US9,499,535 and US9,637,491, that protect the further development of small molecule inhibitor of LRRK2 (Leucine Rich Repeat Kinase 2) within the Company ́s CNS franchise.

Michael Almstetter, CEO and co-founder of Origenis GmbH commented: “These patents significantly strengthen Origenis ́ position in the US as the most important market for developing and commercializing drugs. This protection is key as we develop our small molecule protein kinase inhibitors for a broad range of neurodegenerative and neuroinflammatory diseases.“

Dr. Michael Thormann, CSO and co-founder of Origenis GmbH added: “Together with the respective PET tracers in our programs, we are not only able to facilitate therapeutic development, but also to offer unique and innovative diagnostic and precision medicine approaches on their own. Thus Origenis will continue its way towards completely novel therapeutic and diagnostic concepts with first-in-class potential in several CNS indications that impose a huge threat to an aging population and represent market opportunities with great unmet medical need.”

Read More...

 

Origenis GmbH and Mestrelab Research SL announce a collaboration to develop and market physico-chemical properties prediction software

13. April 2015

Origenis GmbH and Mestrelab Research SL announce a collaboration to develop and market physico-chemical properties prediction software

Munich, Germany – 13 April 2015 – The Spanish scientific software company Mestrelab Research SL and the German Biotechnology company Origenis GmbH announced today that they have entered into a collaboration to jointly develop a set of physic-chemical property prediction plugins for Mestrelab’s software products, which Mestrelab will be responsible for marketing.

The collaboration agreement has been signed following successful proof of concept integration and therefore the path to get these tools to market is expected to be short. The new partners plan to release in excess of 25 different atomic and molecular properties as part of this joint development effort. The collaboration aims to exploit the combination of Mestrelab’s large user base and track record of developing highly popular and widely adopted scientific software tools and of Origenis’ know how and excellence in drug design and in the use of LINGO methods to predict structural properties.

Read More...

 

Origenis extends Collaboration and Licensing Agreement with Major Pharmaceutical Company.

02. May 2013

Origenis extends Collaboration and Licensing Agreement with Major Pharmaceutical Company


Origenis today announced that it extended a Collaboration and Licensing Agreement with a major pharmaceutical company to optimize and transfer small molecule drugs for important therapeutic targets. The alliance combines Origenis' capabilities in compound design, chemical synthesis, and screening with the collaborator’s applied biology, pharmacology, and development expertise in therapeutics.

During the long standing collaboration, Origenis successfully employed its proprietary small molecule discovery platform MOREsystem® to design, synthesize, and characterize novel molecules acting against different targets. Under the extended agreement, Origenis will deliver development candidates with defined properties for certain targets.

Dr. Michael Thormann, Managing Director at Origenis said: “This new agreement underlines the quality of the compounds transferred in the past and the power of our technology platform as well as our interdisciplinary approach and expertise applied to development compounds and commitment of our company in the small molecule drug sector.”

Under the terms of the agreement, the collaborator will receive rights to develop products against defined molecular targets for any indication. Origenis will receive research payments and is eligible for certain development milestones and also royalties on sales.

Read More...

 

 

Origenis receives grant to develop new diagnostic tools for the treatment of
neurodegenerative disorders

28.February 2012

Origenis receives grant to develop new diagnostic tools for the treatment of neurodegenerative disorders

Origenis has started the development of biomarkers to complement the preclinical in-house development of its therapeutic small molecule inhibitors acting on LRRK2. LRRK2 inhibitors are expected to be useful for the treatment of Parkinson’s disease and other neurodegenerative disorders. The objective of this biomarker program is the development of fluorine labeled, LRRK2 specific, CNS penetrating compounds that will be used to visualize the disease progression in animal Parkinson’s models. Origenis receives a two-years-grant from the Leading-Edge Cluster program “m4 – Personalized Medicine and Targeted Therapies”.

Read More...

 

 

Cippix Online Shop Opened

20.April 2010

Cippix Online Shop opened

Origenis has opened the Cippix Online Shop today. In addition to direct marketing approaches, Cippix users can obtain short term licenses instantaneously in the shop. Cippix licenses are provided for 1 day, 1 1 week, 1 month, 6 months or 1 year. It is simple and safe and takes less than five minutes to get access to the Cippix database. Licenses start with as little as 30 € per day on www.cippix.com. During the license term, the number of Cippix Database searches is unlimited and users have always access to the entire database content which is updated weekly.

 

 

Cippix Website Launched

01.October 2009

Cippix Website Launched

Origenis has launched the Cippix Website www.cippix.com today. The website introduces Origenis Patent Chemistry Database Cippix to a broad range of Information Specialists, Patent Researchers, and Research Scientists. Technical background information on Documents and Chemical Entity Search is given along with Screenshots and Sample Reports generated with Cippix Report Generator. Cippix supports all major operating systems and modern web browsers over a secure, certified https line.

 

 

Cippix Database and Cippix Navigator Launched

01.July 2009

Cippix Database and Cippix Navigator Launched

Origenis has built Cippix Database, a patent chemistry centered database. Cippix Database contains more than 3 Million patent documents with more than 1 billion compound references. Cippix Navigator provides powerful search capabilities to find patent documents, chemical names, and chemical structures. Origenis Chemical Content Recognition is used to extract all kinds of chemical entities automatically from multilanguage fulltext patent applications and granted patents ranging back more than fourty years. Every week, 30.000 documents are updated or added. Users need a license to access Cippix Database, which can be obtained from Origenis. Cippix fuels Origenis R&D with up-to-date industry-relevant patent information.

 

 

 

Origenis Receives Grant by the BmBF to Deepen Research in the Anti-inflammatory Sector

15.March 2009

Origenis receives Grant by the BmBF to Deepen Research in the Anti-inflammatory Sector

Origenis receives a research grant from the Federal Ministry of Education and Research to extend its research in the antiinflammatory area. Within this project a consortium of experts, led by Origenis, develops small molecules against the interleukin-mediated autoimmune disease Colitis ulcerosa. The grant will provide a non-repayable fund to Origenis in the amount of 1.2 million €. 

 

 

Origenis Broadens Research Alliance with Alcon to Develop Novel Ophthalmic Compounds

23.October 2008

Origenis Broadens Research Alliance with Alcon to Develop Novel Ophthalmic Compounds

Munich, Germany, October 23, 2008 - Origenis GmbH today announced that it broadened its drug discovery research alliance with Alcon Research, Ltd. (ARL) to create and develop small molecule drugs for important ophthalmic targets. ARL is an affiliate of Alcon, Inc. (NYSE:ACL), the world’s largest eye care company. The alliance combines Origenis' capabilities in compound design, chemical synthesis, and screening with Alcon's applied biology, pharmacology, and development expertise in ophthalmology.

Read More...

 

Alcon Announces Two Agreements Designed to Expand Future Drug Portfolio

15.October 2008

Alcon Announces Two Agreements Designed to Expand Future Drug Portfolio 

Alcon has executed a new agreement and broadened an existing agreement with two different companies to expand its products under development. Alcon entered into a licensing agreement with GlaxoSmithKline for global ophthalmic rights to cilomilast, a phosphodiesterase IV inhibitor. In addition to this new agreement, Alcon expanded its existing drug research alliance with Origenis GmbH with a focus on the discovery and development of the small molecules that might one day have a role in the treatment of eye diseases. Both agreements were signed by Alcon’s affi liate, Alcon Research, Ltd.

Read More...

 

Aureus Pharma Licenses AurWEB to Origenis

06.September 2006

Aureus Pharma licenses AurWEB to Origenis

Paris, FRANCE, September 2006 - Aureus Pharma a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, announces that Origenis, a Swiss-German based company who offers creative services in drug design, synthesis and characterization has become the first customer subscribing to its AurWEB portal.

 

 

Wall Street Reporter Presents Origenis 

19.July 2006

Wall Street Reporter presents Origenis

Munich, Germany, July 2006. Dr. Michael Thormann, Managing Director and Co-Founder, talks about Origenis in an interview with Wall Street Reporter (WSR).

 

 

Origenis Extends Research Alliance with Alcon to Develop Novel Ophthalmic Compounds 

05.July 2006

Origenis Extends Research Alliance with Alcon to Develop Novel Ophthalmic Compounds

Munich, Germany, June, 2006 - Origenis GmbH today announced that it has extended the research alliance with Alcon Research, Ltd. to develop small molecule drugs against important ophthalmic targets for two years. The alliance combines Origenis' compound design and synthesis capabilities with Alcon's applied biology expertise, screening capabilities and development expertise. 

Read More...

 

Origenis Presents at Sportfire Conference

16.May 2006

Origenis presents at Sportfire Conference

Origenis presents its proprietary multiparametric process for Drug Design, Synthesis and Characterisation at the Sportfire User Conference.

 

 

Origenis Starts its operations

21.October 2005

Origenis starts its operations 

Origenis starts successfully its operations, after a management buy-out of the former technology group of Morphochem AG